ZEISS partnership news – Germany-based ZEISS and Mindpeak partners to Advance mIF

Mindpeak’s expertise in AI-based image analysis of pathological tissues, particularly through its established algorithms for clinical routine applications, complements ZEISS's advanced instruments and software for research applications of mIF. The joint solution will integrate both companies' existing offerings to enhance the value for the users and address multiple market segments.

Read also - Alstin Capital funding news – Munich-based Alstin Capital has Secured €175 Million in Funding

Felix Faber, CEO at Mindpeak said, “Mindpeak’s established product portfolio of clinical AI algorithms, which currently supports pathologists in assessing immunohistochemistry (IHC), hematoxylin and eosin (H&E) stained slides, will be extended to mIF in this promising partnership,” “We are thrilled to combine our expertise in AI pathology with ZEISS’s instrumentation to create a streamlined workflow from slide to report for our customers.”

Michael Albiez, Head of ZEISS Research Microscopy Solutions said, “At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Mindpeak marks a significant milestone in advancing workflows for translational and clinical pathology, Together, we are introducing an integrated solution that streamlines mIF workflows and improves reproducibility to meet the evolving needs of both translational research and clinical settings. By combining ZEISS' imaging expertise with Mindpeak's AI-driven analytics, we aim to enable researchers and clinicians to gain deeper insights with greater efficiency and precision.”

The partnership combines complementary competencies and expands both companies’ reach in the growing mIF market. ZEISS and Mindpeak will make their first joint appearance at the ESSB (European Society for Molecular Biomarkers) Conference in Berlin, December 12-13, 2024, showcasing the new mIF solution to pathologists and researchers. Additional details will be shared as the development of the platform progresses.

About Mindpeak

Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Mindpeak’s platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care.